GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more
GeneOne Life Science Inc (011000) - Net Assets
Latest net assets as of September 2025: ₩55.36 Billion KRW
Based on the latest financial reports, GeneOne Life Science Inc (011000) has net assets worth ₩55.36 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩125.54 Billion) and total liabilities (₩70.19 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩55.36 Billion |
| % of Total Assets | 44.09% |
| Annual Growth Rate | 5.25% |
| 5-Year Change | -13.1% |
| 10-Year Change | 117.06% |
| Growth Volatility | 84.56 |
GeneOne Life Science Inc - Net Assets Trend (2009–2024)
This chart illustrates how GeneOne Life Science Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeneOne Life Science Inc (2009–2024)
The table below shows the annual net assets of GeneOne Life Science Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩85.61 Billion | -23.22% |
| 2023-12-31 | ₩111.49 Billion | -38.56% |
| 2022-12-31 | ₩181.47 Billion | -11.67% |
| 2021-12-31 | ₩205.45 Billion | +108.56% |
| 2020-12-31 | ₩98.51 Billion | +309.43% |
| 2019-12-31 | ₩24.06 Billion | -18.19% |
| 2018-12-31 | ₩29.41 Billion | -19.51% |
| 2017-12-31 | ₩36.54 Billion | +1.92% |
| 2016-12-31 | ₩35.85 Billion | -9.09% |
| 2015-12-31 | ₩39.44 Billion | +13.55% |
| 2014-12-31 | ₩34.73 Billion | +46.48% |
| 2013-12-31 | ₩23.71 Billion | -11.33% |
| 2012-12-31 | ₩26.74 Billion | -20.87% |
| 2011-12-31 | ₩33.79 Billion | +5.49% |
| 2010-12-31 | ₩32.04 Billion | -19.38% |
| 2009-12-31 | ₩39.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneOne Life Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35569.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩350.45 Billion | 409.38% |
| Total Equity | ₩85.61 Billion | 100.00% |
GeneOne Life Science Inc Competitors by Market Cap
The table below lists competitors of GeneOne Life Science Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unitron Tech Co Ltd
KQ:142210
|
$53.79 Million |
|
NVR (NVE.SG)
STU:NVE
|
$53.79 Million |
|
DIRTT Environmental Solutions Ltd
PINK:DRTTF
|
$53.81 Million |
|
Realia Business S.A.
LSE:0KBV
|
$53.81 Million |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
$53.77 Million |
|
Jeil Pharmaceutical Co Ltd
KO:271980
|
$53.77 Million |
|
F & M Bank Corp
OTCQX:FMBM
|
$53.77 Million |
|
Grown Rogue International Inc
OTCQB:GRUSF
|
$53.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneOne Life Science Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 111,489,207,550 to 85,605,242,600, a change of -25,883,964,950 (-23.2%).
- Net loss of 48,536,607,370 reduced equity.
- New share issuances of 3,589,704,360 increased equity.
- Other factors increased equity by 19,062,938,060.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-48.54 Billion | -56.7% |
| Share Issuances | ₩3.59 Billion | +4.19% |
| Other Changes | ₩19.06 Billion | +22.27% |
| Total Change | ₩- | -23.22% |
Book Value vs Market Value Analysis
This analysis compares GeneOne Life Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.77x to 1.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩1405.71 | ₩1083.00 | x |
| 2018-12-31 | ₩1131.42 | ₩1083.00 | x |
| 2019-12-31 | ₩1010.43 | ₩1083.00 | x |
| 2020-12-31 | ₩2208.87 | ₩1083.00 | x |
| 2021-12-31 | ₩2657.72 | ₩1083.00 | x |
| 2022-12-31 | ₩2340.29 | ₩1083.00 | x |
| 2023-12-31 | ₩1424.52 | ₩1083.00 | x |
| 2024-12-31 | ₩1072.35 | ₩1083.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneOne Life Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -135.88%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.77x
- Recent ROE (-56.70%) is below the historical average (-33.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -35.27% | -40.48% | 0.65x | 1.34x | ₩-10.73 Billion |
| 2014 | -18.69% | -26.36% | 0.60x | 1.17x | ₩-9.96 Billion |
| 2015 | 3.58% | 4.98% | 0.59x | 1.21x | ₩-2.53 Billion |
| 2016 | -43.51% | -49.72% | 0.48x | 1.83x | ₩-19.18 Billion |
| 2017 | -64.94% | -87.33% | 0.60x | 1.25x | ₩-27.38 Billion |
| 2018 | -40.45% | -34.69% | 0.70x | 1.68x | ₩-14.84 Billion |
| 2019 | -31.66% | -18.47% | 0.81x | 2.13x | ₩-10.02 Billion |
| 2020 | -18.93% | -44.93% | 0.30x | 1.39x | ₩-28.50 Billion |
| 2021 | -7.76% | -41.22% | 0.16x | 1.21x | ₩-36.50 Billion |
| 2022 | -21.02% | -78.31% | 0.22x | 1.23x | ₩-56.30 Billion |
| 2023 | -69.75% | -193.44% | 0.27x | 1.35x | ₩-88.92 Billion |
| 2024 | -56.70% | -135.88% | 0.24x | 1.77x | ₩-57.10 Billion |
Industry Comparison
This section compares GeneOne Life Science Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $228,573,457,868
- Average return on equity (ROE) among peers: -11.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneOne Life Science Inc (011000) | ₩55.36 Billion | -35.27% | 1.27x | $53.78 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |